Vasopressin analogue
From Wikipedia, the free encyclopedia
Biological targetVasopressin receptor
| Vasopressin analogue | |
|---|---|
| Drug class | |
 Vasopressin | |
| Class identifiers | |
| Use | Diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, etc. |
| ATC code | H01BA |
| Biological target | Vasopressin receptor |
| Legal status | |
| In Wikidata | |
Vasopressin analogues are synthetic peptides structurally and functionally similar to arginine vasopressin (AVP), a naturally occurring hormone in mammals. These compounds have been developed to target specific vasopressin receptors (V1, V2, and V3) with varying affinities, allowing for more tailored therapeutic applications. These analogues have been developed to address limitations of endogenous vasopressin, such as short half-life and lack of receptor selectivity, and to potentially reduce side effects associated with non-selective vasopressin receptor activation.[1][2]
